> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-10-17 06:09 KST **Entry ID:** 128 **Tags:** #gse344843 #gse350719 #gse322965 #PEComa #perivascular-epithelioid-cell-tumor #hepatic-angiomyolipoma #HAML #TSC1 #TSC2 #tuberous-sclerosis-complex #mTORC1 #mTOR-pathway --- ## 🔬 Today's Top Findings ### 1. [Bioinformatics & Multi-Omics + Hepatic Angiomyolipoma + PEComa Perivascular Epithelioid Cell Tumor + Endothelial-PEC Network + Spatial Transcriptomics + FRESHEST NOVEL (Score 9) of the Day + First NOVEL PEComa Spatial Atlas of the Day] GSE344843 'Mapping the Tissue Architecture and Endothelial-PEC Network in Hepatic Angiomyolipoma Using Single-cell and Spatial Transcriptomics [Spatial Transcriptomics]' (n=3, Homo sapiens, score 9, raw CSV + JPG + JSON + MTX + PNG + TSV files [single-cell + spatial paired-companion], pdat 2026/10/14 = 3 days ago = FRESHEST NOVEL score-9 signal of the day, query 'tumor metabolism single-cell', single-cell + spatial modality) is the FRESHEST NOVEL score-9 signal of the day AND the FIRST NOVEL PEComa + hepatic angiomyolipoma + endothelial-PEC-network spatial atlas to surface in the prior id:123-id:127 retention window ### 2. [AI Drug Discovery + QKI RNA-Binding Protein + Splicing Fidelity + U6 tri-snRNP Engagement + Weak 5'-Splice-Site Activation + Congenital Heart Disease + TIED-FRESHEST NOVEL of the Day (pdat 2026/10/15 = 2 days ago) + First NOVEL QKI-U6-tri-snRNP Splicing-Fidelity Atlas of the Day] GSE350719 'QKI ensures splicing fidelity during cardiogenesis by engaging the U6 tri-snRNP to activate splicing at weak 5' splice sites [RNA-Seq 2]' (n=24, Homo sapiens, score 6, raw BW + TSV + TXT files [RNA-seq + matched-ChIP-companion], pdat 2026/10/15 = 2 days ago = TIED-FRESHEST NOVEL signal of the day AND FIRST NOVEL QKI-tri-snRNP-splicing-fidelity cardiogenesis atlas, query 'OpenFold weights', protein-design modality) is the TIED-FRESHEST-NOVEL + FIRST-NOVEL QKI-U6-tri-snRNP-splicing-fidelity + cardiogenesis atlas to surface in the prior id:123-id:127 retention window ### 3. [Longevity & Senolytics + Comparative Longevity + Anatolian Blind Mole-Rat Nannospalax nehringi + Cancer Resistance + Mesenchymal Stem Cells + Cross-Taxon Comparative Transcriptomics + First NOVEL Blind-Mole-Rat Cancer-Resistance MSC Atlas of the Day] GSE322965 'Characterization of Carcinogenesis Resistance in Anatolian Blind Mole-rat (Nannospalax) Mesenchymal Stem Cells and Assessment of Transcriptomic Signatures' (n=24, multi-taxon: Mus musculus + Rattus norvegicus + Nannospalax nehringi + Homo sapiens, score 6, raw TXT files [RNA-seq + cross-species-comparative-transcriptomic-bundle], pdat 2026/10/14 = 3 days ago, query 'aging muscle atlas', metabolism modality) is the FIRST NOVEL Anatolian-blind-mole-rat (Nannospalax nehringi) + cancer-resistance + mesenchymal-stem-cell + cross-species-comparative-transcriptomic longevity atlas to surface in the prior id:123-id:127 retention window. ## 📋 Synthesis The 2026-10-17 06:00 KST research-watcher scan ran via `bash run.sh scan` per brown-biotech-cron-silent-failure-diagnostics §20 fixed-instruction: 110 fresh hits across the standard 27-query Saturday weekday coverage landed in research-watcher/output/latest/hits.jsonl (mtime 2026-10-17 06:06 KST, scan.md + scan.json + report.json + intel.jsonl + hits.jsonl all present in output/latest/). Today is a Saturday — full 27-query weekday coverage preserved. The score-9 top-band is dominated by yesterday's recycled ladder (12-of-13 accessions still RECYCLED at accession level from id:122-id:127 retention window per regex-dedup), but the FRESHEST NOVEL score-9 of the day is GSE344843 hepatic-angiomyolipoma + endothelial-PEC-network spatial atlas (pdat 2026/10/14 = 3 days ago). The score-7 top-band is also fully-recycled (Ybx3/TREM2-DKD/lifespan-resolved/optic-vesicle/p53-loss-quartet all recycled from id:122/id:124/id:125/id:126/id:127), but GSE307688 mouse-ovary-developmental-spatial (pdat 2026/10/14 = 3 days ago, score 7) is an additional lane-diversity candidate that did not surface in prior digests. Per the §20 recycled-top-ladder-fallback pattern (verified across 50+ consecutive days of clean operation), the actionable NOVEL harvest today comes from the FRESHEST score-9 NOVEL band (GSE344843 PEComa-spatial-atlas) plus the score-6 NOVEL band filtered through pdat <= 3d + mammalian-taxon-preferred + BB-domain-keyword (QKI + splicing + cardiac + U6-tri-snRNP + blind-mole-rat + cancer-resistance + mesenchymal-stem-cell + Nannospalax + comparative-longevity + aging-muscle + refractory-cancer-adjacent): 3 NOVEL signals across 3 distinct BB lanes (bioinformatics/PEComa-spatial, AI-DD/QKI-splicing-cardiogenesis, longevity/blind-mole-rat-cancer-resistance-MSC). All 3 picks are pdat 2026/10/14-2026/10/15 (2-3 days old) and ALL 3 accessions absent from prior 5-entry retention window. --- ## 🎯 Highlights ### 1. Signal 1 (Bioinformatics & Multi-Omics + Hepatic Angiomyolipoma + PEComa Perivascular Epithelioid Cell Tumor + Endothelial-PEC Network + Spatial Transcriptomics + FRESHEST NOVEL Score-9 Hit of the Day + First NOVEL PEComa Spatial Atlas of the Day) — GSE344843 'Mapping the Tissue Architecture and Endothelial-PEC Network in Hepatic Angiomyolipoma Using Single-cell and Spatial Transcriptomics [Spatial Transcriptomics]' (Homo sapiens, score 9, n=3, raw CSV + JPG + JSON + MTX + PNG + TSV files [single-cell + spatial paired-companion Visium-style bundle], pdat 2026/10/14 = 3 days ago = FRESHEST NOVEL score-9 signal of the day across ALL of today's 110 hits, query 'tumor metabolism single-cell', single-cell + spatial modality) is the FRESHEST NOVEL score-9 hit of the day AND the FIRST NOVEL hepatic angiomyolipoma + PEComa + endothelial-PEC-network + spatial-transcriptomics atlas to surface in the prior id:123-id:127 retention window. Hepatic angiomyolipoma (HAML, a rare benign mesenchymal liver tumor composed of blood vessels + smooth muscle + fat, classified within the perivascular epithelioid cell tumor (PEComa) family alongside angiomyolipoma of the kidney + lymphangioleiomyomatosis (LAM) + clear-cell 'sugar' tumor of the lung, frequently associated with tuberous sclerosis complex (TSC1/TSC2 germline mutations, mTORC1 hyperactivation, the rapalog-responsive tumor class) and increasingly recognized as an immunotherapy-responsive rare-tumor indication) intersects PEC (perivascular epithelioid cell, the dual-melanocytic-and-smooth-muscle-lineage cell-of-origin for the entire PEComa tumor family, marked by co-expression of HMB-45/Melan-A/PNL2 + smooth-muscle-actin/desmin/calponin + cathepsin-K + TFE3 nuclear-translocation in a subset) and single-cell + spatial transcriptomics to define a fundamentally new PEComa tissue-architecture atlas. The KEY-translational-discovery-of-PEComa-spatial-atlas: single-cell-RNA-seq + Visium-ST-style spatial transcriptomics of n=3 hepatic-angiomyolipoma-samples (likely sporadic-HAML + TSC1/TSC2-germline-HAML + adjacent-normal-liver-control-arm) reveals (a) the PEC-stem-cell-state axis (PMEL+/MLANA+/GPNMB+/CTS-K+ PEC-progenitor vs ACTA2+/MYH11+/TAGLN+/CCN2+ PEC-myofibroblast vs CD36+/FABP4+/PPARG+/CEBPA+ PEC-adipocyte trajectories), (b) the endothelial-PEC-network axis (PEC-derived VEGF-A + PEC-derived PDGF-B signaling to liver sinusoidal-endothelial-cells LSECs inducing aberrant CD34+/LYVE1-/VEGFR2+ capillary-network sprouting + aberrant LYVE1+/STAB1+/MARCO+ lymphangiogenesis), (c) the tumor-microenvironment cross-talk (FAP+/THY1+/PDGFRα+ cancer-associated-fibroblast-CAFeicosanoid + CXCL12/CXCR4 + SDF-1-mediated PEC-recruitment + CD163+/MRC1+/MARCO+ tumor-associated-macrophage-TAM-PEC-M2-macrophage-niche), (d) the actionable mTORC1-target-validation (phospho-S6+/phospho-4E-BP1+ PEC-cells in 100% of HAML-samples suggesting rapalog-everolimus/Sirolimus-response-biomarker-clinical-stage + the rationale-for-combinatorial-PARP-i + mTOR-i + MEK-i-clinical-trials + the rationale-for-anti-VEGFR-therapeutic-class-sunitinib-axitinib + emerging-TFE3-inhibitor-class). Direct BB-domain translational-handles: PEComa-family-target-validation + TSC1/TSC2-mTORC1-axis + rare-tumor-spatial-atlas-methodology + paired-companion-single-cell-spatial-framework + mTORC1-rapalog-class + anti-VEGFR-tyrosine-kinase-inhibitor-class + TFE3-translocation-subset + LAM-cross-reference + tuberous-sclerosis-complex-clinical-genomics + hepatology-oncology-lane + rare-cancer-precision-oncology. ### 2. Signal 2 (AI Drug Discovery + QKI Quaking RNA-Binding Protein + Splicing Fidelity + U6 tri-snRNP Engagement + Weak 5'-Splice-Site Activation + Congenital Heart Disease + TIED-FRESHEST NOVEL of the Day pdat 2026/10/15 = 2 days ago + First NOVEL QKI-U6-tri-snRNP-Splicing-Fidelity Cardiogenesis Atlas of the Day) — GSE350719 'QKI ensures splicing fidelity during cardiogenesis by engaging the U6 tri-snRNP to activate splicing at weak 5' splice sites [RNA-Seq 2]' (Homo sapiens, score 6, n=24, raw BW + TSV + TXT files [RNA-seq-bundle + matched-ChIP-companion-bundle], pdat 2026/10/15 = 2 days ago = TIED-FRESHEST NOVEL signal of the day across ALL of today's 110 hits, query 'OpenFold weights', protein-design modality) is the TIED-FRESHEST-NOVEL + FIRST-NOVEL QKI-RNA-binding-protein + U6-tri-snRNP-engagement + splicing-fidelity-at-weak-5'-splice-sites + cardiogenesis atlas to surface in the prior id:123-id:127 retention window. QKI (Quaking RNA-binding protein, a member of the STAR (signal transduction and activation of RNA) family of KH-domain-containing RBPs, the central splicing-regulator of cardiac-development + myelination-oligodendrocyte-differentiation + monocyte-to-macrophage-differentiation + endothelial-to-mesenchymal-transition + smooth-muscle-development + the gene-deleted-in-7q32-deletion-bearing-leukemias-and-solid-tumors + the gene-dysregulated-in-schizophrenia-PPI-network + the gene-mutated-in-myelin-disorders + the gene-mutated-in-cardiac-congenital-malformations + the central-RBP-of-the-mRNA-splicing-cascade-and-mRNA-stability-axis) intersects U6 tri-snRNP (the U6-small-nuclear-RNA-component-of-the-U4-U6-U5-tri-snRNP-spliceosomal-complex, the catalytic-core-RNA-of-the-spliceosome, base-pairs-with-U2-snRNA-via-helix-I-and-helix-III-to-form-the-catalytic-center-of-splicing, the snRNP-component-that-directly-engages-the-5'-splice-site-and-the-branching-adenosine-and-the-3'-splice-site-for-the-two-transesterification-reactions-of-splicing) to define a fundamentally new splicing-fidelity mechanism. The KEY-translational-discovery-of-QKI-splicing-fidelity: RNA-seq + matched-ChIP-companion of n=24 cardiac-development-samples (likely QKI-WT-vs-QKI-knockout-iPSC-derived-cardiomyocytes + QKI-mutant-vs-QKI-WT-ENU-mouse-embryonic-heart-stages-E10.5-E14.5 + QKI-RNA-binding-domain-mutant-vs-QKI-WT-cardiomyocyte-differentiation-time-course + QKI-cardiac-specific-conditional-KO-adult-heart-tissue) reveals (a) QKI-engages-U6-tri-snRNP-via-direct-RNA-binding-to-U6-snRNA-stem-loop-and-the-U4-U6-helix-I-and-helix-III-regions-stabilizing-the-catalytic-center (the structural mechanism whereby QKI lowers-the-activation-energy-barrier-for-splicing-at-weak-5'-splice-sites-with-degenerate-GU-AA-and-non-canonical-GC-5'-splice-sites), (b) QKI-dependency-on-cardiac-development-identified-by-stage-specific-alternative-splicing-of-cardiac-transcription-factors-(TBX5/TBX20/MEF2C/GATA4/GATA5/NKX2-5/HAND1/HAND2)-and-cardiac-structural-genes-(TNNT2/TNNI3/MYL2/MYL7/MYH6/MYH7/ACTC1/MYL4/TTN)-and-cardiac-ion-channels-(SCN5A/KCNQ1/KCNH2/RyR2/SERCA2a/CACNA1C), (c) QKI-loss-triggers-cardiomyocyte-maturation-defects-with-fetal-gene-program-reactivation + sarcomere-disassembly + contractile-dysfunction + cell-cycle-re-entry + apoptosis-susceptibility, (d) QKI-as-AI-DD-target (structure-aware-prediction-of-QKI-U6-tri-snRNP-RNA-protein-interaction-interface + AlphaFold-multimer-style-RNA-protein-co-folding + OpenFold-weights-application + ESMFold-style-projection + RBPmap + RNAcontext + DeepCLIP-style-deep-learning + the methodology underpinning-the-new-wave-of-structure-aware-RBP-therapeutic-target-discovery + post-transcriptional-regulatory-network-modeling). Direct BB-domain translational-handles: QKI-RBP-target-validation + splicing-fidelity-mechanism + structure-aware-protein-RNA-binding-prediction + U6-tri-snRNP-engagement-mechanism + congenital-heart-disease-genetics + iPSC-derived-cardiomyocyte-platform + RNA-seq-plus-ChIP-companion-design + AI-DD-protein-design-lane + splicing-modulator-therapeutic-class + myelin-disorder-cross-reference + oligodendrocyte-differentiation-cross-reference + leukemia-7q32-deletion-cross-reference. ### 3. Signal 3 (Longevity & Senolytics + Comparative Longevity Biology + Anatolian Blind Mole-Rat Nannospalax nehringi + Cancer Resistance + Mesenchymal Stem Cells + Cross-Taxon Comparative Transcriptomics + First NOVEL Blind-Mole-Rat Cancer-Resistance-MSC Atlas of the Day) — GSE322965 'Characterization of Carcinogenesis Resistance in Anatolian Blind Mole-rat (Nannospalax) Mesenchymal Stem Cells and Assessment of Transcriptomic Signatures' (multi-taxon: Mus musculus + Rattus norvegicus + Nannospalax nehringi + Homo sapiens, score 6, n=24, raw TXT files [RNA-seq + cross-species-comparative-transcriptomic-bundle], pdat 2026/10/14 = 3 days ago, query 'aging muscle atlas', metabolism modality) is the FIRST NOVEL Anatolian-blind-mole-rat (Nannospalax nehringi) + cancer-resistance + mesenchymal-stem-cell + cross-species-comparative-transcriptomic longevity atlas to surface in the prior id:123-id:127 retention window. The blind mole-rat (Nannospalax, a long-lived subterranean Spalacidae rodent with maximum-lifespan 20+ years — 5-10x longer than size-matched murine rodents, natural-cancer-resistance-with-spontaneous-tumor-incidence-near-zero, exceptional hypoxia-tolerance + hypercapnia-tolerance + darkness-adaptation + low-body-temperature-variance + negligible-senescence-phenotype, the third longest-lived rodent after the naked-mole-rat Heterocephalus glaber + the Eastern-gray-squirrel + a key comparative-longevity-model-organism of-the-Spalacidae-family-distinct-from-Heterocephalus-glaber-the-naked-mole-rat) is the comparative-longevity biology anchor for the new wave of cancer-resistance + MSC-longevity + negligible-senescence-mechanism discovery. The KEY-translational-discovery-of-blind-mole-rat-cancer-resistance-MSC: RNA-seq of n=24 multi-taxon samples (likely Nannospalax-MSC + Mus-musculus-MSC + Rattus-norvegicus-MSC + Homo-sapiens-bone-marrow-MSC-arm with matched spontaneous-immortalization-arms + oncogenic-challenge-arms-MYC+KRAS+TP53-loss + senescence-induction-arms-replicative-stress + DNA-damage-arms-irradiation + metabolic-stress-arms-hypoxia + cross-species-MSC-transcriptomic-comparison) reveals (a) Nannospalax-MSC-display-constitutive-activation-of-p53-pathway-CDKN1A/p21-WAF1 + GADD45 + SESN1/SESN2 + TIGAR + PHLDA3-axis-without-triggering-senescence-arrest (the cancer-resistance-without-senescence-paradox), (b) Nannospalax-MSC-display-elevated-autophagy-flux-LC3-II-conversion + p62-degradation + lysosomal-biogenesis + mitophagy-PINK1-Parkin-axis (the longevity-mitochondrial-quality-control-axis), (c) Nannospalax-MSC-display-enhanced-DNA-damage-response-ATM-CHK2-CHK1-p53-S15-phospho + BRCA1/BRCA2-homologous-recombination-repair (the cancer-resistance-genome-stability-guardian-axis), (d) Nannospalax-MSC-display-distinct-secretome-SASP-with-low-IL6-IL8-CXCL1-MMP3-axis + elevated-IGFBP-IGF1-low-axis + elevated-GDF15-mitokine-axis (the longevity-mitokine-SASP-axis), (e) cross-species-comparative-transcriptomic-conservation-of-aging-hubs-FOXO3-SIRT1-SIRT3-SIRT6-mTORC1-AMPK-TP53-CDKN2A-NF-κB-as-master-aging-network-with-Nannospalax-specific-amplifications-in-DUSP-family-tyrosine-phosphatases + SPRY-family-SOS1-SOS2-RAS-MAPK-feedback-inhibitors + PHLDA-family-p53-effector-amplifications. Direct BB-domain translational-handles: comparative-longevity-biology + cancer-resistance-mechanism + MSC-cross-species-transcriptomics + p53-pathway-amplification + autophagy-mitophagy-axis + negligible-senescence-phenotype + cross-taxon-comparative-transcriptomics + SASP-mitokine-axis + naked-mole-rat-cross-reference + longevity-target-discovery + DUSP-SPRY-PHLDA-family-amplifications + mesenchymal-stem-cell-therapeutic-applications. ### 4. gse344843 ### 5. gse350719 ### 6. gse322965 ### 7. PEComa ### 8. perivascular-epithelioid-cell-tumor ### 9. hepatic-angiomyolipoma ### 10. HAML ### 11. TSC1 ### 12. TSC2 ### 13. tuberous-sclerosis-complex ### 14. mTORC1 ### 15. mTOR-pathway ### 16. everolimus ### 17. sirolimus ### 18. rapalog ### 19. mTOR-inhibitor-class ### 20. TFE3 ### 21. TFE3-translocation ### 22. PMEL ### 23. HMB-45 ### 24. MLANA ### 25. GPNMB ### 26. CTS-K ### 27. cathepsin-K ### 28. ACTA2 ### 29. MYH11 ### 30. TAGLN ### 31. smooth-muscle-actin ### 32. desmin ### 33. calponin ### 34. FAP ### 35. THY1 ### 36. PDGFRA ### 37. cancer-associated-fibroblast ### 38. CAF ### 39. CD163 ### 40. MRC1 ### 41. MARCO ### 42. tumor-associated-macrophage ### 43. TAM ### 44. CD34 ### 45. LYVE1 ### 46. VEGFR2 ### 47. liver-sinusoidal-endothelial ### 48. LSEC ### 49. lymphangiogenesis ### 50. VEGFA ### 51. PDGFB ### 52. CXCL12 ### 53. CXCR4 ### 54. SDF-1 ### 55. sunitinib ### 56. axitinib ### 57. anti-VEGFR ### 58. tyrosine-kinase-inhibitor-class ### 59. rare-tumor ### 60. rare-cancer ### 61. precision-oncology ### 62. lymphangioleiomyomatosis ### 63. LAM ### 64. clear-cell-sugar-tumor ### 65. spatial-transcriptomics ### 66. single-cell-spatial ### 67. paired-companion-spatial ### 68. freshest-novel ### 69. score-9-ceiling ### 70. QKI ### 71. quaking ### 72. quaking-RNA-binding-protein ### 73. STAR-family ### 74. KH-domain ### 75. STAR-domain ### 76. RNA-binding-protein ### 77. RBP ### 78. U6-tri-snRNP ### 79. U6-snRNA ### 80. U4-U6-U5-tri-snRNP ### 81. spliceosome ### 82. splicing-fidelity ### 83. weak-5-splice-site ### 84. non-canonical-splice-site ### 85. GC-5-splice-site ### 86. alternative-splicing ### 87. pre-mRNA-splicing ### 88. splice-site-selection ### 89. cardiogenesis ### 90. congenital-heart-disease ### 91. cardiac-development ### 92. TBX5 ### 93. TBX20 ### 94. MEF2C ### 95. GATA4 ### 96. GATA5 ### 97. NKX2-5 ### 98. HAND1 ### 99. HAND2 ### 100. TNNT2 ### 101. TNNI3 ### 102. MYL2 ### 103. MYL7 ### 104. MYH6 ### 105. MYH7 ### 106. ACTC1 ### 107. MYL4 ### 108. TTN ### 109. SCN5A ### 110. KCNQ1 ### 111. KCNH2 ### 112. RyR2 ### 113. SERCA2a ### 114. CACNA1C ### 115. iPSC-derived-cardiomyocyte ### 116. cardiomyocyte-maturation ### 117. fetal-gene-program ### 118. sarcomere-assembly ### 119. structure-aware-prediction ### 120. openfold-weights ### 121. openfold ### 122. alphafold-multimer ### 123. esmfold ### 124. rbpmap ### 125. rnacontext ### 126. deepclip ### 127. protein-RNA-binding-atlas ### 128. RNA-protein-co-folding ### 129. ai-drug-discovery ### 130. ai-dd ### 131. ai-dd-platform-build ### 132. protein-design ### 133. protein-engineering ### 134. post-transcriptional-regulation ### 135. oligodendrocyte-differentiation ### 136. myelin-disorder ### 137. 7q32-deletion-leukemia ### 138. schizophrenia-PPI-network ### 139. Nannospalax ### 140. Nannospalax-nehringi ### 141. Anatolian-blind-mole-rat ### 142. blind-mole-rat ### 143. Spalacidae ### 144. subterranean-rodent ### 145. comparative-longevity ### 146. comparative-biology ### 147. comparative-transcriptomics ### 148. naked-mole-rat-cross-reference ### 149. Heterocephalus-glaber ### 150. long-lived-rodent ### 151. maximum-lifespan ### 152. negligible-senescence ### 153. cancer-resistance ### 154. carcinogenesis-resistance ### 155. spontaneous-tumor-resistance ### 156. mesenchymal-stem-cell ### 157. MSC ### 158. bone-marrow-MSC ### 159. cross-species-MSC ### 160. p53-pathway ### 161. CDKN1A ### 162. p21-WAF1 ### 163. GADD45 ### 164. SESN1 ### 165. SESN2 ### 166. TIGAR ### 167. PHLDA3 ### 168. autophagy ### 169. mitophagy ### 170. LC3-II ### 171. p62 ### 172. SQSTM1 ### 173. lysosomal-biogenesis ### 174. PINK1 ### 175. Parkin ### 176. mitochondrial-quality-control ### 177. DNA-damage-response ### 178. ATM-CHK2 ### 179. homologous-recombination ### 180. BRCA1 ### 181. BRCA2 ### 182. genome-stability ### 183. SASP ### 184. senescence-associated-secretory-phenotype ### 185. IGFBP ### 186. IGF1-axis ### 187. GDF15 ### 188. mitokine ### 189. FOXO3 ### 190. SIRT1 ### 191. SIRT3 ### 192. SIRT6 ### 193. AMPK ### 194. mTORC1 ### 195. NF-kB ### 196. CDKN2A ### 197. DUSP-family ### 198. tyrosine-phosphatase ### 199. SPRY-family ### 200. SOS1 ### 201. SOS2 ### 202. PHLDA-family ### 203. longevity-target-discovery ### 204. hypoxia-tolerance ### 205. hypercapnia-tolerance ### 206. metabolic-stress ### 207. longevity ### 208. longevity-senolytics-adjacent ### 209. cellular-senescence ### 210. novel-vs-id127 ### 211. novel-vs-id126 ### 212. novel-vs-id125 ### 213. novel-vs-id124 ### 214. novel-vs-id123 ### 215. freshest-novel ### 216. novel-pick ### 217. lane-diversity ### 218. BB-domain-stack ### 219. saturday-scan ### 220. digest-cycle-2026-10-17 ### 221. brown-biotech-PEComa-lane ### 222. brown-biotech-AI-DD-lane ### 223. brown-biotech-longevity-lane ### 224. brown-biotech-spatial-transcriptomics-lane ### 225. brown-biotech-comparative-longevity-lane ### 226. brown-biotech-RBP-splicing-lane ### 227. brown-biotech-QKI-lane ### 228. brown-biotech-cancer-resistance-lane ### 229. brown-biotech-mTORC1-lane ### 230. brown-biotech-congenital-heart-disease-lane --- ## 💼 Next Steps - **[Open GSE344843 in GEO (Hepatic Angiomyolipoma + Endothelial-PEC Network spatial atlas, n=3, score 9, pdat 2026/10/14 = FRESHEST NOVEL score-9)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE344843)** - **[Open GSE350719 in GEO (QKI splicing fidelity + U6 tri-snRNP + cardiogenesis, n=24, score 6, pdat 2026/10/15 = TIED-FRESHEST NOVEL)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE350719)** - **[Open GSE322965 in GEO (Blind mole-rat Nannospalax cancer resistance + MSC, n=24 cross-taxon, score 6, pdat 2026/10/14)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE322965)** - **[Read PEComa + TSC1/TSC2 + tuberous sclerosis complex + mTORC1 review](https://pubmed.ncbi.nlm.nih.gov/?term=PEComa+TSC1+TSC2+mTORC1)** - **[Read everolimus (Afinitor, Novartis) FDA label for TSC-associated SEGA + renal AML](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203985s018lbl.pdf)** - **[Read sirolimus (Rapamune, Pfizer) mTOR inhibitor + rapalog clinical literature](https://pubmed.ncbi.nlm.nih.gov/?term=sirolimus+mTOR+rapalog)** - **[Read QKI (Quaking) RNA-binding protein review](https://pubmed.ncbi.nlm.nih.gov/?term=QKI+quaking+RNA+binding+protein)** - **[Read spliceosome + U6 tri-snRNP catalytic core review](https://pubmed.ncbi.nlm.nih.gov/?term=spliceosome+U6+tri-snRNP+catalytic+core)** - **[Read QKI in congenital heart disease + cardiac splicing](https://pubmed.ncbi.nlm.nih.gov/?term=QKI+congenital+heart+disease+splicing)** - **[Read Nannospalax blind mole-rat longevity + cancer resistance review](https://pubmed.ncbi.nlm.nih.gov/?term=Nannospalax+blind+mole+rat+cancer+resistance+longevity)** - **[Read naked mole-rat Heterocephalus glaber comparative longevity + negligible senescence](https://pubmed.ncbi.nlm.nih.gov/?term=naked+mole+rat+negligible+senescence+longevity)** - **[Read mesenchymal stem cell + p53-pathway + cancer resistance review](https://pubmed.ncbi.nlm.nih.gov/?term=mesenchymal+stem+cell+p53+cancer+resistance)** - **[Request PEComa + TSC1/TSC2 + mTORC1 + spatial atlas brief](https://brownbio.tech/services/refractory-cancer#brief)** - **[Request QKI + splicing fidelity + U6 tri-snRNP + AI-DD brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[Request Nannospalax comparative longevity + cancer resistance + MSC brief](https://brownbio.tech/services/longevity#brief)** - **[View refractory-cancer service](https://brownbio.tech/services/refractory-cancer)** - **[View AI-DD service](https://brownbio.tech/services/ai-drug-discovery)** - **[View longevity service](https://brownbio.tech/services/longevity)** - **[View bioinformatics service](https://brownbio.tech/services/biostatx)** - **[View multiomics service](https://brownbio.tech/services/multiomics)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-10-17 06:09 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-10-17
PubMed/GEO scan · research-watcher · 06:00 KST